{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:22:27Z","timestamp":1793229747185,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01845-6","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T03:33:53Z","timestamp":1764128033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trophoblast cell surface antigen 2 (TROP2) from ascitic extracellular vesicles drives peritoneal metastasis of ovarian cancer by mesothelial-to-mesenchymal transition"],"prefix":"10.1186","volume":"18","author":[{"given":"Guangyan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"3","key":"1845_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1845_CR2","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2022;29(4):2617\u201325.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1845_CR3","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12(5):2115\u201332.","journal-title":"Theranostics."},{"key":"1845_CR4","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"1845_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1Suppl 1","key":"1845_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1Suppl 1):61\u201385.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"1845_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer. Int J Gynaecol Obstet. 2023;162(2):383\u201394.","journal-title":"Int J Gynaecol Obstet."},{"issue":"1","key":"1845_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D CORT\u00e9S-GUIRAL","year":"2021","unstructured":"CORT\u00e9S-GUIRAL D, H\u00fcBNER M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1845_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05267-8","volume":"22","author":"S Rahmati","year":"2024","unstructured":"Rahmati S, Moeinafshar A, Rezaei N. The multifaceted role of extracellular vesicles (EVs) in colorectal cancer: metastasis, immune suppression, therapy resistance, and autophagy crosstalk. J Transl Med. 2024;22(1):452.","journal-title":"J Transl Med"},{"issue":"1","key":"1845_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/path.4695","volume":"239","author":"P Sandoval","year":"2016","unstructured":"Sandoval P, Jim\u00e9nez-Heffernan JA, Guerra-Azcona G, et al. Mesothelial-to-mesenchymal transition in the pathogenesis of post-surgical peritoneal adhesions. J Pathol. 2016;239(1):48\u201359.","journal-title":"J Pathol."},{"issue":"21","key":"1845_CR11","doi-asserted-by":"publisher","first-page":"null","DOI":"10.3390\/ijms222111496","volume":"22","author":"L Pascual-Ant\u00f3n","year":"2021","unstructured":"Pascual-Ant\u00f3n L, Carde\u00f1es B, De La Sains R, et al. Mesothelial-to-Mesenchymal transition and exosomes in peritoneal metastasis of ovarian cancer. Int J Mol Sci. 2021;22(21):null.","journal-title":"Int J Mol Sci."},{"issue":"Suppl 3","key":"1845_CR12","first-page":"S5","volume":"20","author":"N di Paolo","year":"2000","unstructured":"di Paolo N, Sacchi G. Atlas of peritoneal histology. Periton Dialysis Int. 2000;20(Suppl 3):S5-96.","journal-title":"Periton Dialysis Int."},{"issue":"4","key":"1845_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/path.4281","volume":"231","author":"P Sandoval","year":"2013","unstructured":"Sandoval P, Jim\u00e9nez-Heffernan JA, Rynne-Vidal \u00c1, et al. Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol. 2013;231(4):517\u201331.","journal-title":"J Pathol."},{"issue":"4","key":"1845_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/cancers7040872","volume":"7","author":"A Rynne-Vidal","year":"2015","unstructured":"Rynne-Vidal A, Jim\u00e9nez-Heffernan JA, Fern\u00e1ndez-Chac\u00f3n C, et al. The mesothelial origin of carcinoma Associated-Fibroblasts in peritoneal metastasis. Cancers (Basel). 2015;7(4):1994\u20132011.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1845_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/path.4889","volume":"242","author":"A Rynne-Vidal","year":"2017","unstructured":"Rynne-Vidal A, Au-Yeung CL, Jim\u00e9nez-Heffernan JA, et al. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol. 2017;242(2):140\u201351.","journal-title":"J Pathol."},{"issue":"9","key":"1845_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1614856","volume":"8","author":"F Antony","year":"2019","unstructured":"Antony F, Deantonio C. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology. 2019;8(9):e1614856.","journal-title":"Oncoimmunology"},{"key":"1845_CR17","doi-asserted-by":"crossref","unstructured":"Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7(11):925-34.","DOI":"10.1016\/S1470-2045(06)70939-1"},{"issue":"1","key":"1845_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-020-01570-6","volume":"39","author":"S Tan","year":"2020","unstructured":"Tan S, Xia L, Yi P, et al. Exosomal MiRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;39(1):67.","journal-title":"J Exp Clin Cancer Res."},{"key":"1845_CR19","doi-asserted-by":"crossref","unstructured":"Jin Y, Zhang Z, Yu Q, et al. Positive reciprocal feedback of LncRNA ZEB1-AS1 and HIF-1\u03b1 contributes to Hypoxia-Promoted tumorigenesis and metastasis of pancreatic cancer. Front Oncol. 2021;11(1):761979.","DOI":"10.3389\/fonc.2021.761979"},{"issue":"21","key":"1845_CR20","doi-asserted-by":"publisher","first-page":"null","DOI":"10.3390\/cells11213392","volume":"11","author":"Q QU","year":"2022","unstructured":"QU Q, LIU L, CUI Y, et al. Exosomes from human omental Adipose-Derived mesenchymal stem cells secreted into Ascites promote peritoneal metastasis of epithelial ovarian cancer [J]. Cells. 2022;11(21):null.","journal-title":"Cells"},{"key":"1845_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, Lebleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020. https:\/\/doi.org\/10.1126\/science.aau6977.","journal-title":"Science"},{"issue":"3","key":"1845_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.devcel.2019.04.011","volume":"49","author":"I Wortzel","year":"2019","unstructured":"Wortzel I, Kenific CM, Lyden D. Exosome-Mediated metastasis: communication from a distance. Dev Cell. 2019;49(3):347\u201360.","journal-title":"Dev Cell."},{"issue":"7576","key":"1845_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature15376","volume":"527","author":"L Zhang","year":"2015","unstructured":"Zhang L, Zhang S, Yao J, et al. Microenvironment-induced PTEN loss by Exosomal MicroRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100\u20134.","journal-title":"Nature."},{"key":"1845_CR24","doi-asserted-by":"crossref","unstructured":"Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and Immunogenic tumour-derived exosomes. Lancet. 2002;360(9329):295\u2013305.","DOI":"10.1016\/S0140-6736(02)09552-1"},{"key":"1845_CR25","doi-asserted-by":"crossref","unstructured":"Xiong J, Fu F, Yu F, He X. Advances of Exosomal MiRNAs in the diagnosis and treatment of ovarian cancer. Discov Oncol. 2023;14(1):65.","DOI":"10.1007\/s12672-023-00674-7"},{"issue":"6","key":"1845_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-022-02560-y","volume":"42","author":"G Li","year":"2023","unstructured":"Li G, Yi X. Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition. Oncogene. 2023;42(6):421\u201333.","journal-title":"Oncogene"},{"issue":"null","key":"1845_CR27","first-page":"1342367","volume":"13","author":"JH M\u00fcller","year":"2023","unstructured":"M\u00fcller JH, Plage H. Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas [J]. Front Oncol. 2023;13(null):1342367.","journal-title":"Front Oncol"},{"issue":"4","key":"1845_CR28","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1073\/pnas.1905384117","volume":"117","author":"EC Hsu","year":"2020","unstructured":"Hsu EC, Rice MA, Bermudez A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020;117(4):2032\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1845_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89(4):245\u201358.","journal-title":"Pathobiology"},{"key":"1845_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108296","volume":"239","author":"X Liu","year":"2022","unstructured":"Liu X, Deng J, Yuan Y, et al. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296.","journal-title":"Pharmacol Ther"},{"key":"1845_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jare.2023.05.012","volume":"58","author":"W Tang","year":"2024","unstructured":"Tang W, Hu Y, Tu K, et al. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2\/\u03b2-catenin positive feedback loop. J Adv Res. 2024;58:193\u2013210.","journal-title":"J Adv Res"},{"issue":"1","key":"1845_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01899-6","volume":"40","author":"C Wang","year":"2021","unstructured":"Wang C, Wang J, Shen X, et al. LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1. J Exp Clin Cancer Res. 2021;40(1):101.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1845_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100520","volume":"22","author":"W Zhou","year":"2023","unstructured":"Zhou W, Ma J, Zhao H, et al. Serum exosomes from epithelial ovarian cancer patients contain LRP1, which promotes the migration of epithelial ovarian cancer cell. Mol Cell Proteomics. 2023;22(4):100520.","journal-title":"Mol Cell Proteomics"},{"issue":"23","key":"1845_CR34","doi-asserted-by":"publisher","first-page":"e2310134","DOI":"10.1002\/advs.202310134","volume":"11","author":"B Chai","year":"2024","unstructured":"Chai B, Wu Y, Yang H, et al. Tau Aggregation-Dependent lipid peroxide accumulation driven by the hsa_circ_0001546\/14-3-3\/CAMK2D\/Tau complex inhibits epithelial ovarian cancer peritoneal metastasis. Adv Sci (Weinh). 2024;11(23):e2310134.","journal-title":"Adv Sci (Weinh)."},{"issue":"6","key":"1845_CR35","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","volume":"164","author":"M Tkack","year":"2016","unstructured":"Tkack M, Th\u00e9ry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226\u201332.","journal-title":"Cell."},{"key":"1845_CR36","doi-asserted-by":"crossref","unstructured":"Gong X, Chi H, Strohmer DF, et al. Exosomes: A potential tool for immunotherapy of ovarian cancer. Front Immunol. 2022;13(null):1089410.","DOI":"10.3389\/fimmu.2022.1089410"},{"issue":"7","key":"1845_CR37","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1111\/cas.15793","volume":"114","author":"Y Kimura","year":"2023","unstructured":"Kimura Y, Ohzawa H, Miyato H, et al. Intraperitoneal transfer of microRNA-29b-containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer [J]. Cancer Sci. 2023;114(7):2939\u201350.","journal-title":"Cancer Sci"},{"key":"1845_CR38","doi-asserted-by":"crossref","unstructured":"Guan X, Zong ZH, Liu Y, et al. circPUM1 promotes tumorigenesis and progression of ovarian cancer by sponging miR-615-5p and miR-6753-5p. Mol Ther Nucleic Acids. 2019;18(null):882-92.","DOI":"10.1016\/j.omtn.2019.09.032"},{"issue":"null","key":"1845_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2024.07.002","volume":"189","author":"B Mcnamara","year":"2024","unstructured":"Mcnamara B, Greenman M. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecol Oncol. 2024;189(null):16\u201323.","journal-title":"Gynecol Oncol"},{"key":"1845_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.120312","volume":"207","author":"Y Fu","year":"2020","unstructured":"Fu Y, Jing Y, Gao J, et al. Variation of Trop2 on non-small-cell lung cancer and normal cell membranes revealed by super-resolution fluorescence imaging [J]. Talanta. 2020;207:120312.","journal-title":"Talanta"},{"key":"1845_CR41","doi-asserted-by":"crossref","unstructured":"Hu Y, Zhu Y, Qi D, et al. Trop2-targeted therapy in breast cancer. Biomark Res. 2024;12(1):82.","DOI":"10.1186\/s40364-024-00633-6"},{"issue":"15","key":"1845_CR42","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","volume":"30","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Balar AV, Petrylak DP, et al. Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer. Clin Cancer Res. 2024;30(15):3179\u201388.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1845_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2174\/1568009622666220407111013","volume":"22","author":"T Yang","year":"2022","unstructured":"Yang T, Jia L. TROP2 down-regulated DSG2 to promote gastric cancer cell invasion and migration by EGFR\/AKT and DSG2\/PG\/\u03b2-catenin pathways [j]. Curr Cancer Drug Targets. 2022;22(8):691\u2013702.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"1845_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li C, Liu J, Yang X, et al. Theranostic application of (64)Cu\/(177)Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50(1):168\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1845_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50215-z","volume":"14","author":"S Liu","year":"2024","unstructured":"Liu S, Hawley SJ, Kunder CA, et al. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024;14(1):486.","journal-title":"Sci Rep"},{"issue":"8","key":"1845_CR46","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741\u201351.","journal-title":"N Engl J Med"},{"issue":"19","key":"1845_CR47","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of Anti-Trop-2 antibody drug conjugate sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic Triple-Negative breast cancer. J Clin Oncol. 2017;35(19):2141\u20138.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1845_CR48","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"22","key":"1845_CR49","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1845_CR50","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S. Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30(12):3709\u201316.","journal-title":"Nat Med"},{"issue":"10411","key":"1845_CR51","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, MARm\u00e9 F, et al. Overall survival with sacituzumab Govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333.","journal-title":"Lancet"},{"issue":"29","key":"1845_CR52","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41(29):4678\u201387.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1845_CR53","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","volume":"31","author":"S Zhao","year":"2025","unstructured":"Zhao S, Cheng Y, Wang Q, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials. Nat Med. 2025;31(6):1976\u201386.","journal-title":"Nat Med"},{"issue":"8Supplement","key":"1845_CR54","first-page":"LB030","volume":"83","author":"N H","year":"2023","unstructured":"H N, Yang C, Yang Y, et al. Abstract LB030: SHR-A1921, a novel TROP-2 ADC with an optimized design and well-balanced profile between efficacy and safety [J]. Cancer Res. 2023;83(8Supplement):LB030-LB.","journal-title":"Cancer Res"},{"issue":"8Supplement","key":"1845_CR55","doi-asserted-by":"publisher","first-page":"CT181","DOI":"10.1158\/1538-7445.AM2023-CT181","volume":"83","author":"J Wang","year":"2023","unstructured":"Wang J, Song WUL. Abstract CT181: A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors. Cancer Res. 2023;83(8Supplement):CT181-CT.","journal-title":"Cancer Res"},{"issue":"16suppl","key":"1845_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1100","volume":"41","author":"F Ma","year":"2023","unstructured":"Ma F, Qiu F, Tong Z, et al. Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced\/metastatic solid tumors. J Clin Oncol. 2023;41(16suppl):1100.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1845_CR57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/1535-7163.MCT-22-0352","volume":"22","author":"E Guerra","year":"2023","unstructured":"Guerra E, Trerotola M, Relli V. 3D-Informed targeting of the Trop-2 Signal-Activation site drives selective cancer vulnerability. Mol Cancer Ther. 2023;22(6):790\u2013804.","journal-title":"Mol Cancer Ther."},{"key":"1845_CR58","doi-asserted-by":"crossref","unstructured":"Kim H, Guerra E,\u00a0BAEK E, et al. Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-selective anti-TROP2 monoclonal antibody, a proprietary site-directed conjugation technology and plasma-stable tumor-selective linker chemistry. Cancer Research, 2022, 82(12_Supplement): 328.","DOI":"10.1158\/1538-7445.AM2022-328"},{"issue":"3","key":"1845_CR59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/path.4188","volume":"230","author":"JP Waters","year":"2013","unstructured":"Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol. 2013;230(3):241\u20138.","journal-title":"J Pathol."},{"issue":"5","key":"1845_CR60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361\u201371.","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"1845_CR61","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2020.1766821","volume":"9","author":"NTH Dinh","year":"2020","unstructured":"Dinh NTH, Lee J, Lee J, et al. Indoor dust extracellular vesicles promote cancer lung metastasis by inducing tumour necrosis factor-\u03b1. J Extracell Vesicles. 2020;9(1):1766821.","journal-title":"J Extracell Vesicles"},{"key":"1845_CR62","doi-asserted-by":"crossref","unstructured":"Trenec M, Chretien B, Silva N, et al. Pos0658\u2005tumor necrosis factor blockers induced sarcoidosis: description of 31 cases from the french pharmacovigilance database.\u00a0Ann Rheum Dis. 2022;81(Suppl 1):601.1.","DOI":"10.1136\/annrheumdis-2022-eular.4378"},{"key":"1845_CR63","doi-asserted-by":"crossref","unstructured":"Liu BX, Xie Y, Zhang J, et al. SERPINB5 promotes colorectal cancer invasion and migration by promoting EMT and angiogenesis via the TNF-\u03b1\/NF-\u03baB pathway. Int Immunopharmacol. 2024;131(null):111759.","DOI":"10.1016\/j.intimp.2024.111759"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01845-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:01:56Z","timestamp":1767063716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01845-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01845-6","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of ascites and tissue specimens was approved by the Research Ethics Committee of Xuzhou Central Hospital (approval number: XZXY-LK-20220927-086). All participants provided informed consent.The research involving animals was approved by the Research Ethics Committee of Xuzhou Medical University (approval number: 202310T021) and was conducted per the university\u2019s guidelines for animal protection and use. The maximum tumor size\/burden did not exceed the tolerance levels permitted by the aforementioned institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}